A prospective pilot study of antibodies against human papillomaviruses and cutaneous squamous cell carcinoma nested in the Oxford component of the European Prospective Investigation into Cancer and Nutrition

Delphine Casabonne, Kristina M. Michael, Tim Waterboer, Michael Pawlita, Ola Forslund, Robert D. Burk, Ruth C. Travis, Tim J. Key, Robert Newton

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

In a prospective pilot study nested in the EPIC-Oxford cohort, we examined the seroprevalence of antibodies against the L1 antigen of 38 human papilloma virus (HPV) types among 39 cases of cutaneous squamous cell carcinoma (SCC) for whom plasma was collected prior to diagnosis (incident) and 80 controls. Fifteen cases having already developed SCC at blood collection (prevalent) were also tested. There were no statistically significant differences in the seroprevalence of antibodies against any of the HPV types examined between incident cases and controls, nor was there a difference in the seroprevalence of multiple infections. However, consistent with results from published case-control studies, the seroprevalence of many β-HPV types was higher among prevalent cases than among either incident cases or controls. For example the seroprevalence of antibodies against HPV-8 was 20% (16/80) in controls, 23% (9/39) among incident cases and 40% (6/15) among prevalent cases. Among the incident cases only, the seroprevalence was 16% (5/32) among those for whom blood was collected 18+ months prior to diagnosis, but 57% (4/7) among those for whom diagnosis was within 18 months of blood collection, a pattern seen for many of the HPV types. This might suggest that if HPV is involved in the aetiology of SCC, the process occurs close to the time of diagnosis, or that the antibody response observed in people with SCC is a consequence of tumor formation. Further and larger prospective studies are needed to clarify the role of HPV in the aetiology of cutaneous SCC.

Original languageEnglish (US)
Pages (from-to)1862-1868
Number of pages7
JournalInternational Journal of Cancer
Volume121
Issue number8
DOIs
StatePublished - Oct 15 2007

Fingerprint

Papillomaviridae
Seroepidemiologic Studies
Squamous Cell Carcinoma
Prospective Studies
Skin
Antibodies
Neoplasms
Leukocyte L1 Antigen Complex
Antibody Formation
Case-Control Studies

Keywords

  • Cutaneous squamous cell carcinoma (SCC)
  • Epidemiology
  • Human papillomavirus (HPV)
  • Prospective case-control
  • Serology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A prospective pilot study of antibodies against human papillomaviruses and cutaneous squamous cell carcinoma nested in the Oxford component of the European Prospective Investigation into Cancer and Nutrition. / Casabonne, Delphine; Michael, Kristina M.; Waterboer, Tim; Pawlita, Michael; Forslund, Ola; Burk, Robert D.; Travis, Ruth C.; Key, Tim J.; Newton, Robert.

In: International Journal of Cancer, Vol. 121, No. 8, 15.10.2007, p. 1862-1868.

Research output: Contribution to journalArticle

Casabonne, Delphine ; Michael, Kristina M. ; Waterboer, Tim ; Pawlita, Michael ; Forslund, Ola ; Burk, Robert D. ; Travis, Ruth C. ; Key, Tim J. ; Newton, Robert. / A prospective pilot study of antibodies against human papillomaviruses and cutaneous squamous cell carcinoma nested in the Oxford component of the European Prospective Investigation into Cancer and Nutrition. In: International Journal of Cancer. 2007 ; Vol. 121, No. 8. pp. 1862-1868.
@article{3bb7e264f1ee477d81f0226257ba9f95,
title = "A prospective pilot study of antibodies against human papillomaviruses and cutaneous squamous cell carcinoma nested in the Oxford component of the European Prospective Investigation into Cancer and Nutrition",
abstract = "In a prospective pilot study nested in the EPIC-Oxford cohort, we examined the seroprevalence of antibodies against the L1 antigen of 38 human papilloma virus (HPV) types among 39 cases of cutaneous squamous cell carcinoma (SCC) for whom plasma was collected prior to diagnosis (incident) and 80 controls. Fifteen cases having already developed SCC at blood collection (prevalent) were also tested. There were no statistically significant differences in the seroprevalence of antibodies against any of the HPV types examined between incident cases and controls, nor was there a difference in the seroprevalence of multiple infections. However, consistent with results from published case-control studies, the seroprevalence of many β-HPV types was higher among prevalent cases than among either incident cases or controls. For example the seroprevalence of antibodies against HPV-8 was 20{\%} (16/80) in controls, 23{\%} (9/39) among incident cases and 40{\%} (6/15) among prevalent cases. Among the incident cases only, the seroprevalence was 16{\%} (5/32) among those for whom blood was collected 18+ months prior to diagnosis, but 57{\%} (4/7) among those for whom diagnosis was within 18 months of blood collection, a pattern seen for many of the HPV types. This might suggest that if HPV is involved in the aetiology of SCC, the process occurs close to the time of diagnosis, or that the antibody response observed in people with SCC is a consequence of tumor formation. Further and larger prospective studies are needed to clarify the role of HPV in the aetiology of cutaneous SCC.",
keywords = "Cutaneous squamous cell carcinoma (SCC), Epidemiology, Human papillomavirus (HPV), Prospective case-control, Serology",
author = "Delphine Casabonne and Michael, {Kristina M.} and Tim Waterboer and Michael Pawlita and Ola Forslund and Burk, {Robert D.} and Travis, {Ruth C.} and Key, {Tim J.} and Robert Newton",
year = "2007",
month = "10",
day = "15",
doi = "10.1002/ijc.22885",
language = "English (US)",
volume = "121",
pages = "1862--1868",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - A prospective pilot study of antibodies against human papillomaviruses and cutaneous squamous cell carcinoma nested in the Oxford component of the European Prospective Investigation into Cancer and Nutrition

AU - Casabonne, Delphine

AU - Michael, Kristina M.

AU - Waterboer, Tim

AU - Pawlita, Michael

AU - Forslund, Ola

AU - Burk, Robert D.

AU - Travis, Ruth C.

AU - Key, Tim J.

AU - Newton, Robert

PY - 2007/10/15

Y1 - 2007/10/15

N2 - In a prospective pilot study nested in the EPIC-Oxford cohort, we examined the seroprevalence of antibodies against the L1 antigen of 38 human papilloma virus (HPV) types among 39 cases of cutaneous squamous cell carcinoma (SCC) for whom plasma was collected prior to diagnosis (incident) and 80 controls. Fifteen cases having already developed SCC at blood collection (prevalent) were also tested. There were no statistically significant differences in the seroprevalence of antibodies against any of the HPV types examined between incident cases and controls, nor was there a difference in the seroprevalence of multiple infections. However, consistent with results from published case-control studies, the seroprevalence of many β-HPV types was higher among prevalent cases than among either incident cases or controls. For example the seroprevalence of antibodies against HPV-8 was 20% (16/80) in controls, 23% (9/39) among incident cases and 40% (6/15) among prevalent cases. Among the incident cases only, the seroprevalence was 16% (5/32) among those for whom blood was collected 18+ months prior to diagnosis, but 57% (4/7) among those for whom diagnosis was within 18 months of blood collection, a pattern seen for many of the HPV types. This might suggest that if HPV is involved in the aetiology of SCC, the process occurs close to the time of diagnosis, or that the antibody response observed in people with SCC is a consequence of tumor formation. Further and larger prospective studies are needed to clarify the role of HPV in the aetiology of cutaneous SCC.

AB - In a prospective pilot study nested in the EPIC-Oxford cohort, we examined the seroprevalence of antibodies against the L1 antigen of 38 human papilloma virus (HPV) types among 39 cases of cutaneous squamous cell carcinoma (SCC) for whom plasma was collected prior to diagnosis (incident) and 80 controls. Fifteen cases having already developed SCC at blood collection (prevalent) were also tested. There were no statistically significant differences in the seroprevalence of antibodies against any of the HPV types examined between incident cases and controls, nor was there a difference in the seroprevalence of multiple infections. However, consistent with results from published case-control studies, the seroprevalence of many β-HPV types was higher among prevalent cases than among either incident cases or controls. For example the seroprevalence of antibodies against HPV-8 was 20% (16/80) in controls, 23% (9/39) among incident cases and 40% (6/15) among prevalent cases. Among the incident cases only, the seroprevalence was 16% (5/32) among those for whom blood was collected 18+ months prior to diagnosis, but 57% (4/7) among those for whom diagnosis was within 18 months of blood collection, a pattern seen for many of the HPV types. This might suggest that if HPV is involved in the aetiology of SCC, the process occurs close to the time of diagnosis, or that the antibody response observed in people with SCC is a consequence of tumor formation. Further and larger prospective studies are needed to clarify the role of HPV in the aetiology of cutaneous SCC.

KW - Cutaneous squamous cell carcinoma (SCC)

KW - Epidemiology

KW - Human papillomavirus (HPV)

KW - Prospective case-control

KW - Serology

UR - http://www.scopus.com/inward/record.url?scp=34548677936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548677936&partnerID=8YFLogxK

U2 - 10.1002/ijc.22885

DO - 10.1002/ijc.22885

M3 - Article

VL - 121

SP - 1862

EP - 1868

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 8

ER -